EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS MSVirtual2020.org #MSVirtual2020 FULL SCIENTIFIC PROGRAM Full Scientific Program as of September 12, 2020. For the most up-to-date program, please visit the MSVirtual2020 Full Online Program. Table of Contents Friday, September 11, 2020 .......................................................................................................................... 4 Plenary Session 1 ...................................................................................................................................... 4 Plenary Session 1: Welcome and Paty Lecture ..................................................................................... 4 Parallel Sessions 1-4 .................................................................................................................................. 4 PS01 - Strategies for disease modification............................................................................................ 4 PS02 - Innate immunity in MS pathology and repair ............................................................................ 5 PS03 - Biomarkers ................................................................................................................................. 6 PS04 - Impact of the environment and lifestyle and MS risk and clinical course ................................. 7 Parallel Sessions 5-8 .................................................................................................................................. 8 PS05 - Pharmacological management of progressive MS .................................................................... 8 PS06 - Lymphocyte subsets in MS ......................................................................................................... 9 PS07 - Radiological advances I (NAIMS/MAGNIMS) ........................................................................... 10 PS08 - Epigenetics and genetic factors ............................................................................................... 11 Saturday, September 12, 2020 ................................................................................................................... 12 Parallel Session 9-12………………………………………………………………………………………………………………………….13 PS09 - Personalized approaches to MS ............................................................................................... 12 PS10 - Gut-CNS axis and the microbiome in MS ................................................................................. 13 PS11 - Radiological advances II ........................................................................................................... 14 PS12 - Sex-related factors in pathogenesis and management ........................................................... 15 European Charcot Foundation Symposium, Nurse’s Session 1, Young Investigator Session 1 .............. 16 CS01 - European Charcot Foundation Symposium ............................................................................. 16 NS01 - Advanced nursing activities ..................................................................................................... 17 YI01 - Young Investigators 1 ................................................................................................................ 17 Parallel Session 13-16 ............................................................................................................................. 18 PS13 - Innovations in symptomatic and rehabilitative therapy .......................................................... 18 PS14 - The impact of MS on neurons and glia .................................................................................... 18 PS15 - Visual outcome measures in MS (IMSVISUAL) ......................................................................... 19 PS16 - Machine learning approaches .................................................................................................. 20 Sunday, September 13 ................................................................................................................................ 22 Hot Topics 1-4 ......................................................................................................................................... 22 HT01 - Strategies to promote remyelination ...................................................................................... 22 HT02 - Aging and multiple sclerosis .................................................................................................... 22 HT03 - Developments in pediatric MS ................................................................................................ 22 HT04 - Grey matter pathology ............................................................................................................ 22 Hot Topics 5-7 ......................................................................................................................................... 23 HT05 - Lymphoid follicles and meningeal involvement in MS ............................................................ 23 HT06 - Global perspectives on neuromyelitis optica spectrum disorders .......................................... 23 HT07 - MOG mediated disease ........................................................................................................... 24 Nurse’s Session 2 and Young Investigator Session 2 .............................................................................. 24 NS02 - Unique contributions of MS nursing ....................................................................................... 24 YI02 - Young Investigators 2 ................................................................................................................ 24 Free Communications 1-4 ....................................................................................................................... 27 Free Communications 1 ...................................................................................................................... 27 FC02 - Free Communications 2 ........................................................................................................... 28 FC03 - Free Communications 3 ........................................................................................................... 29 FC04 - Free Communications 4 ........................................................................................................... 30 Plenary Session 2 .................................................................................................................................... 32 Plenary Session 2 - ACTRIMS-ECTRIMS Lecture and Closing .............................................................. 32 Saturday, September 26 ............................................................................................................................. 32 Late Breaking News ................................................................................................................................. 32 LB01 - Late Breaking News .................................................................................................................. 32 Special Session: COVID-19 ...................................................................................................................... 34 SS02 - COVID-19 .................................................................................................................................. 34 On-Demand Program .................................................................................................................................. 36 Burning Debates ...................................................................................................................................... 36 BD01 - DMTs prevent/slow down cognitive impairment in MS ........................................................... 36 BD02 - DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity ................................................................................................................................................. 36 BD03 - Microglia are protective in MS ................................................................................................. 36 Meet the Experts .................................................................................................................................... 37 MTE01 - CNS in disorders in children .................................................................................................. 37 MTE02 - Neuro-ophthalmology of MS ................................................................................................ 37 MTE03 - B-cell-directed therapy in MS ................................................................................................ 37 MTE04 - Choosing the right MS disease therapy for individual patients ............................................. 37 MTE05 - Immune disorders of the CNS other than MS ....................................................................... 37 Teaching Courses .................................................................................................................................... 37 TC01 - Ultra-high-field (7T) MRI in MS (NAIMS) .................................................................................. 37 TC02 - Neurofilaments and other biomarkers of CNS disease............................................................. 37 TC03 - NMO